Last reviewed · How we verify
Finafloxacin i.v. solution 200 mg
At a glance
| Generic name | Finafloxacin i.v. solution 200 mg |
|---|---|
| Sponsor | MerLion Pharmaceuticals GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Finafloxacin i.v. solution 200 mg CI brief — competitive landscape report
- Finafloxacin i.v. solution 200 mg updates RSS · CI watch RSS
- MerLion Pharmaceuticals GmbH portfolio CI